- Home
- CSBR
as 07-26-2024 4:00pm EST
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALTIMORE |
| Market Cap: | 62.5M | IPO Year: | 1986 |
| Target Price: | $7.50 | AVG Volume (30 days): | 3.9K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.50 - $7.13 | Next Earning Date: | 07-18-2024 |
| Revenue: | $50,155,000 | Revenue Growth: | -6.90% |
| Revenue Growth (this year): | 9.16% | Revenue Growth (next year): | 29.66% |
Stock Insider Trading Activity of Champions Oncology Inc. (CSBR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mendelson Daniel Newman | CSBR | Director | Jan 12 '24 | Buy | $6.50 | 1,000 | $6,500.00 | 198,625 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 11 '24 | Buy | $6.27 | 2,000 | $12,540.00 | 197,625 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 10 '24 | Buy | $6.31 | 2,944 | $18,576.64 | 195,625 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 9 '24 | Buy | $6.25 | 3,000 | $18,750.00 | 192,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 8 '24 | Buy | $6.15 | 1,000 | $6,150.00 | 189,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 5 '24 | Buy | $6.09 | 2,000 | $12,180.00 | 188,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 4 '24 | Buy | $6.12 | 3,000 | $18,360.00 | 186,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Jan 3 '24 | Buy | $5.83 | 500 | $2,915.00 | 183,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Dec 21 '23 | Buy | $4.92 | 2,500 | $12,300.00 | 183,181 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Dec 20 '23 | Buy | $4.82 | 2,100 | $10,122.00 | 180,681 | SEC Form 4 |
| Mendelson Daniel Newman | CSBR | Director | Dec 19 '23 | Buy | $4.75 | 5,000 | $23,750.00 | 178,581 | SEC Form 4 |
Latest Champions Oncology Inc. News
CSBR Breaking Stock News: Dive into CSBR Ticker-Specific Updates for Smart Investing
ACCESSWIRE
8 days ago
Champions Oncology Reports Quarterly Revenue of $14.0 Million
ACCESSWIRE
15 days ago
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
ACCESSWIRE
2 months ago
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Simply Wall St.
2 months ago
Champions Oncology (NASDAQ:CSBR) shareholders have endured a 53% loss from investing in the stock three years ago
Simply Wall St.
3 months ago
Will Champions Oncology (NASDAQ:CSBR) Spend Its Cash Wisely?
Insider Monkey
4 months ago
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Call Transcript
ACCESSWIRE
4 months ago
Champions Oncology Reports Quarterly Revenue of $12.0 Million
ACCESSWIRE
5 months ago
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
Compare CSBR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSBR Champions Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.